Corporate Officers

Daniel M. Junius
  • Daniel M. Junius

    President and Chief Executive Officer

Daniel Junius was promoted to President and Chief Operating Officer of ImmunoGen in July 2008 and became President and Chief Executive Officer of the Company effective January 1, 2009. He joined ImmunoGen as Chief Financial Officer (CFO) and Senior Vice President, Finance in May 2005 and was promoted to Executive Vice President, Finance and CFO in July 2006.

Mr. Junius was Executive Vice President and CFO of New England Business Service, Inc. (NEBS) from 2002 until its acquisition by Deluxe Corporation in 2004 and Senior Vice President and CFO of NEBS from 1998 to 2002. Prior to NEBS, he was Vice President and CFO of Nashua Corporation. He joined Nashua Corporation in 1984 and held financial management positions of increasing responsibility before becoming CFO in 1996. Mr. Junius holds a Masters in Management from Northwestern University's Kellogg School of Management.



David Johnston headshot
  • David B. Johnston

    Executive Vice President and Chief Financial Officer

David Johnston joined ImmunoGen in December 2013 as EVP and CFO bringing to ImmunoGen more than 30 years of experience in corporate finance, including 15 years in senior financial functions at biotechnology companies, as well as extensive experience in corporate planning. Prior to joining ImmunoGen, Mr. Johnston was chief financial officer at AVEO Pharmaceuticals Inc. Prior to joining AVEO in 2007, he was Senior Vice President of Finance, Corporate Planning and Analysis at Genzyme Corporation and, before that, the VP Finance and CFO of Genzyme Biosurgery. Prior to joining Genzyme in 1998, Mr. Johnston held financial, planning and analysis positions of increasing responsibility at several major corporations.  He holds a BS degree from Washington and Lee University and an MBA from the University of Michigan.
 

John M. Lambert, Ph.D.
  • John M. Lambert, Ph.D.

    Executive Vice President, Research and Development and Chief Scientific Officer

John M. Lambert joined ImmunoGen as Senior Director of Research in 1987 and was promoted to Vice President, Research and Development in 1994, to Senior Vice President, Pharmaceutical Development in 2000, to Senior Vice President, Research and Development and Chief Scientific Officer in early 2008, and to Executive Vice President, Research and Development and Chief Scientific Officer in July 2008. Prior to his tenure with ImmunoGen, Dr. Lambert was Assistant Professor of Pathology at the Dana-Farber Cancer Institute in Boston, MA. Dr. Lambert received his doctorate in Biochemistry from Cambridge University in England.



Charles Morris
  • Charles Morris, M.B., Ch.B., M.R.C.P.

    Executive Vice President and Chief Development Officer

Dr. Morris joined ImmunoGen in November 2012 bringing nearly twenty years of experience in the development of anticancer compounds, including experience with registration clinical trials, regulatory approvals, pharmacovigilance, and medical affairs support for marketed products. Prior to joining ImmunoGen, he was the executive vice president and chief medical officer at Allos Therapeutics, Inc., where he led the company's clinical development functions including clinical operations, regulatory, and pharmacovigilance. Prior to joining Allos in 2010, Dr. Morris was vice president worldwide clinical research at Cephalon, Inc., where he contributed significantly to the company achieving its first approved oncology drug, Treanda® (bendamustine). Prior to joining Cephalon in 2007, Dr. Morris was with AstraZeneca Pharmaceuticals (formerly Zeneca Pharmaceuticals), serving most recently as vice president, clinical development projects, oncology. Dr. Morris held a number of leadership roles during his more than ten years with AstraZeneca, including managing the clinical development of all late-stage pipeline and marketed oncology products.

Dr. Morris holds Degrees of Bachelor of Medicine, Bachelor of Surgery, and Bachelor of Medical Science in Clinical Pharmacology and Therapeutics from the Sheffield University Medical School, UK, and is a member of the Royal College of Physicians of London.



Sandra Poole
  • Sandra E. Poole

    Senior Vice President, Technical Operations

Ms. Poole joined ImmunoGen in 2014 from Genzyme, where she was senior vice president of biologics manufacturing. Her 15-year career with Genzyme spanned bio-manufacturing-related functions including heading up technology development, overseeing the construction, start-up, tech transfer and approval of a fully integrated manufacturing operation in Belgium and leading Genzyme’s global network of biologic manufacturing sites. Prior to joining Genzyme in 1999, Ms. Poole oversaw process development and played a key role in establishing technical operations at Canadian-based Biomira, Inc. She holds both a Master and a Bachelor of Applied Science degree from the University of Waterloo (Canada) in chemical engineering and also completed the executive program in business management at the Massachusetts Institute of Technology Sloan School of Management. 

 

Ellie Harrison
  • Ellie Harrison

    Vice President and Chief Human Resources Officer

Ms. Harrison joined ImmunoGen in February 2014 from Blue Cross and Blue Shield of Rhode Island (BCBSRI), where she was Senior Vice President of Human Resources, with responsibility for compensation and benefits, diversity and inclusion, talent management and acquisition, and employee engagement and development. Prior to joining BCBSRI, Ms. Harrison was Senior Human Resources Advisor at Citigroup, serving as head of HR for multiple lines of businesses within its consumer banking division. Prior to joining Citigroup in 2009, Ms. Harrison held high level HR positions of increasing responsibility at Fidelity Investments, which she joined in 1997. Ms. Harrison’s career has also included senior HR positions at Chubb Life America, Banc One Asset Management Company and Healthsource, Inc. She is a graduate of the University of Minnesota.



Godfrey Amphlett
  • Godfrey Amphlett, Ph.D.

    Vice President, Process and Analytical Development

Since joining ImmunoGen in 2001, Dr. Amphlett has built a team with industry-leading expertise in the many areas critical to transforming a promising research compound into a commercially-manufacturable, approvable product. These include process development, formulation development, characterization and analytical methods for both the individual product components as well as for the complete drug product. For example, his team developed the commercial-scale production processes for trastuzumab emtansine (T-DM1) and SAR3419 for Genentech and Sanofi, respectively.

Prior to joining ImmunoGen in 2001, Dr. Amphlett held positions of increasing responsibility at Genetics Institute, now a part of Pfizer, and at Armour Pharmaceuticals, a subsidiary of Revlon Health Care. He earned a B.A. from the University of Cambridge, England, and a Ph.D. from the University of Birmingham, England. Dr. Amphlett did his postdoctoral work at the University of Notre Dame, South Bend, IN.


Craig Barrows
  • Craig Barrows

    Vice President, General Counsel and Secretary

Craig Barrows joined ImmunoGen in October 2007 with over twenty years of legal experience – thirteen as chief corporate legal officer – and a strong transactional background. Mr. Barrows was general counsel of M/A-COM, Inc. from 1994 until the company was acquired in 1996, general counsel and secretary of Media 100 Inc. before he joined New England Business Service, Inc. (NEBS) in 1998, and vice president, general counsel and secretary of NEBS until the company was acquired in 2004. Most recently, Mr. Barrows was vice president, general counsel and assistant secretary of Mercury Computer Systems, Inc. Before transitioning to in-house counsel, Mr. Barrows focused on corporate and securities law at Skadden, Arps, Slate, Meagher & Flom. He earned his undergraduate degree at the University of Chicago and his law degree at Fordham University School of Law.



Eric Guempel head shot
  • Eric Guempel

    Vice President, Product Strategy and Program Management

Mr. Guempel joined ImmunoGen in January 2014 from the Merck Serono division of Merck KGaA, where he was Head of New Therapies and Strategy for the Oncology Franchise. Prior to joining EMD Serono in 2008, Mr. Guempel held positions of increasing responsibility in the Oncology Strategic Business unit of Biogen Idec, including the position of Rituxan® Team Leader. Prior to joining Idec in 2002, he held commercial positions supporting Neupogen®, Neulasta® and other oncology programs at Amgen. Prior to joining the marketing functions in 1998, Mr. Guempel held clinical research-related positions of increasing responsibility at Amgen, Berlex, and Ciba-Geigy (now Novartis). He holds an MS degree in Biology from Seton Hall University and an MBA from Pepperdine University.


Bob Lutz
  • Robert J. Lutz, Ph.D.

    Vice President, Translational Research and Development

Dr. Lutz has held positions of increasing responsibility since joining ImmunoGen as a Scientist in 1992. He gained broad responsibility for ImmunoGen’s preclinical development functions with his promotion to Senior Director of Preclinical Development in 2004 and to Executive Director, Preclinical Development in 2007. In early 2010, he gained added responsibility for project management, becoming Executive Director, Drug Development.

Dr. Lutz leads functions that provide support essential to the successful advancement of ImmunoGen and partner new product candidates from research through clinical development and the leveraging of findings in the clinic to further enhance ImmunoGen’s proprietary product pipeline. He earned a B.S. from the University of New Hampshire, NH, and a Ph.D. from Brandeis University, MA. Dr. Lutz did his postdoctoral work at the Eleanor Roosevelt Institute for Cancer Research, Denver, CO.



Peter Williams
  • Peter Williams

    Vice President, Business Development

Mr. Williams brings to ImmunoGen over twenty years of business development, deal negotiation and technology in- and out-licensing experience. Prior to joining ImmunoGen in August 2009, he was Senior Director of Business Development at Alnylam Pharmaceuticals, Inc., where he played a central role in the successful execution of large out-licensing and alliance transactions with global pharmaceutical companies. His positions prior to joining Alnylam include being Senior Director of Business Development at Millennium Pharmaceuticals, where he led several major alliances and transactions, and Associate Director, Office of Technology Licensing & Industry Sponsored Research, at Harvard Medical School, where he led activities related to commercializing in-house technology innovations. Mr. Williams has a Masters of Science degree in Management Science (accredited MBA) from the Imperial College of Science, Technology & Medicine, University of London, UK, and a Bachelors of Science degree in Biology from the University of Sussex, UK.



Theresa Wingrove, Ph.D.
  • Theresa Wingrove, Ph.D.

    Vice President, Regulatory Affairs

Dr. Wingrove joined ImmunoGen in early 2011 with over twenty years of regulatory and clinical management experience in the healthcare industry. Before joining ImmunoGen, she was the vice president of regulatory and clinical affairs at Histogenics, where her responsibilities included authoring and gaining approval of a SPA for a Phase III trial for a novel biologic and other regulatory responsibilities in the US and Europe. Prior to that, she was the senior director of regulatory and clinical affairs at MediSpectra, where she was responsible for the full spectrum of regulatory support – from start of clinical testing through marketing approval – for a novel cancer diagnostic product. Prior to joining MediSpectra, Dr. Wingrove was at Pfizer-Infusaid for over ten years, during which time she executed the clinical and regulatory programs associated with the company's combination products. She holds a BS in Biochemistry from Brown University and a doctorate in Biochemical Toxicology from the University of Rochester.



Last updated October 22, 2014